Insulet (NASDAQ:PODD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a research report released on Saturday morning,Wall Street Zen reports.

Several other research firms have also recently issued reports on PODD. Wells Fargo & Company cut Insulet from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $255.00 to $144.00 in a report on Wednesday, August 5th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $152.00 price objective (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Evercore set a $180.00 price objective on Insulet in a research note on Monday, July 6th. Barclays raised Insulet to a “hold” rating in a research note on Wednesday, October 7th. Finally, Royal Bank Of Canada decreased their target price on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $186.68.

Insulet Stock Up 3.3%

NASDAQ PODD opened at $139.81 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company’s 50 day simple moving average is $141.13 and its 200 day simple moving average is $158.56. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a market capitalization of $9.70 billion, a P/E ratio of 26.13, a PEG ratio of 1.07 and a beta of 1.11.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts expect that Insulet will post 6.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

A number of large investors have recently made changes to their positions in PODD. MV Capital Management Inc. acquired a new stake in shares of Insulet in the fourth quarter worth about $29,000. Elevation Wealth Partners LLC boosted its stake in shares of Insulet by 115.6% during the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 104 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Insulet by 4,620.0% during the 1st quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 231 shares during the last quarter. State of Wyoming increased its holdings in shares of Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after acquiring an additional 73 shares during the last quarter. Finally, Continuum Advisory LLC acquired a new position in shares of Insulet during the 2nd quarter valued at about $46,000.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.